Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-β1 Signaling in Kidney

References

• NogueiraA, PiresMJ, OliveiraPA. Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In Vivo. 2017;31(1):1–22. doi:10.21873/invivo28064215
   PubMed Web of Science ®Google Scholar
• TaoZ, ShiA, ZhaoJ. Epidemiological perspectives of diabetes. Cell Biochem Biophys. 2015;73(1):181–185. doi:10.1007/s12013-015-0598-425711186
   PubMed Web of Science ®Google Scholar
• BoseM, AlmasS, PrabhakarS. Wnt signaling and podocyte dysfunction in diabetic nephropathy. J Investig Med. 2017;65(8):1093–1101. doi:10.1136/jim-2017-000456
   PubMed Web of Science ®Google Scholar
• LvW, FanF, WangY, et al. Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD. Physiol Genomics. 2018;50(1):20–34. doi:10.1152/physiolgenomics.00039.201729127220
   PubMed Web of Science ®Google Scholar
• SunYB, QuX, CaruanaG, LiJ. The origin of renal fibroblasts/myofibroblasts and the signals that trigger fibrosis. Differentiation. 2016;92(3):102–107. doi:10.1016/j.diff.2016.05.00827262400
   PubMed Web of Science ®Google Scholar
• KimKK, SheppardD, ChapmanHA. TGF-beta1 signaling and tissue fibrosis. Cold Spring Harb Perspect Biol. 2018;10(4):a022293. doi:10.1101/cshperspect.a02229328432134
   PubMed Web of Science ®Google Scholar
• MaL, LiH, ZhangS, et al. Emodin ameliorates renal fibrosis in rats via TGF-beta1/Smad signaling pathway and function study of Smurf 2. Int Urol Nephrol. 2018;50(2):373–382. doi:10.1007/s11255-017-1757-x29230704
   PubMed Web of Science ®Google Scholar
• LobodaA, SobczakM, JozkowiczA, DulakJ. TGF-beta1/Smads and miR-21 in renal fibrosis and inflammation. Mediators Inflamm. 2016;2016:8319283. doi:10.1155/2016/831928327610006
   PubMed Web of Science ®Google Scholar
• HigginsSP, TangY, HigginsCE, et al. TGF-beta1/p53 signaling in renal fibrogenesis. Cell Signal. 2018;43:1–10. doi:10.1016/j.cellsig.2017.11.00529191563
   PubMed Web of Science ®Google Scholar
• ZhangQ, LiJ, TanXP, ZhaoQ. Effects of ME3 on the proliferation, invasion and metastasis of pancreatic cancer cells through epithelial-mesenchymal transition. Neoplasma. 2019;66:896–907. doi:10.4149/neo_2019_190119N5931607129
   PubMed Web of Science ®Google Scholar
• SanajouD, Ghorbani HaghjoA, ArganiH, et al. Reduction of renal tubular injury with a RAGE inhibitor FPS-ZM1, valsartan and their combination in streptozotocin-induced diabetes in the rat. Eur J Pharmacol. 2019;842:40–48. doi:10.1016/j.ejphar.2018.10.03530393200
   PubMed Web of Science ®Google Scholar
• ShermanB, HernandezAM, AlhadoM, MengeL, PriceRS. Silibinin differentially decreases the aggressive cancer phenotype in an in vitro model of obesity and prostate cancer. Nutr Cancer. 2019;72:1–10.31842617
   PubMed Web of Science ®Google Scholar
• KoJW, ShinNR, ParkSH, et al. Silibinin inhibits the fibrotic responses induced by cigarette smoke via suppression of TGF-beta1/Smad 2/3 signaling. Food Chem Toxicol. 2017;106(Pt A):424–429. doi:10.1016/j.fct.2017.06.01628602599
   PubMed Web of Science ®Google Scholar
• CaoY, ZhangL, WangY, FanQ, CongY. Astragaloside IV attenuates renal fibrosis through repressing epithelial-to-mesenchymal transition by inhibiting microRNA-192 expression: in vivo and in vitro studies. Am J Transl Res. 2019;11(8):5029–5038.31497219
   PubMed Web of Science ®Google Scholar
• CaoT, XuR, XuY, et al. The protective effect of Cordycepin on diabetic nephropathy through autophagy induction in vivo and in vitro. Int Urol Nephrol. 2019;51(10):1883–1892. doi:10.1007/s11255-019-02241-y31359358
   PubMed Web of Science ®Google Scholar
• YanT, ChoppM, NingR, et al. Intracranial aneurysm formation in type-one diabetes rats. PLoS One. 2013;8(7):e67949. doi:10.1371/journal.pone.006794923844137
   PubMed Web of Science ®Google Scholar
• WangX, ConstansMM, ChebibFT, TorresVE, PellegriniL. Effect of a vasopressin V2 receptor antagonist on polycystic kidney disease development in a rat model. Am J Nephrol. 2019;49(6):487–493. doi:10.1159/00050066731117065
   PubMed Web of Science ®Google Scholar
• Duborija-KovacevicN, TomicZ. Kidney, skeletal muscle and myocardium as potential target sites of pygeum africanum toxicity in wistar rats. Rev Int Androl. 2019;17(1):8–14. doi:10.1016/j.androl.2017.12.00630691591
   PubMed Web of Science ®Google Scholar
• JingW, VaziriND, NunesA, et al. LCZ696 (Sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD. Am J Transl Res. 2017;9(12):5473–5484.29312499
   PubMed Web of Science ®Google Scholar
• ZannadF, FerreiraJP. Is sacubitril/valsartan antifibrotic? J Am Coll Cardiol. 2019;73(7):807–809. doi:10.1016/j.jacc.2018.11.04130784674
   PubMed Web of Science ®Google Scholar
• HuangQF, LiY, WangJG. Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients. Drug Des Devel Ther. 2013;8:79–86. doi:10.2147/DDDT.S38617
   PubMed Web of Science ®Google Scholar
• GiotiK, PapachristodoulouA, BenakiD, et al. Silymarin enriched extract (Silybum marianum) additive effect on doxorubicin-mediated cytotoxicity in PC-3 prostate cancer cells. Planta Med. 2019;85(11–12):997–1007.31288278
   PubMed Web of Science ®Google Scholar
• KhazimK, GorinY, CavaglieriRC, AbboudHE, FantiP. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo. Am J Physiol Renal Physiol. 2013;305(5):F691–F700. doi:10.1152/ajprenal.00028.201323804455
   PubMed Web of Science ®Google Scholar
• ChenDQ, HuHH, WangYN, et al. Natural products for the prevention and treatment of kidney disease. Phytomedicine. 2018;50:50–60. doi:10.1016/j.phymed.2018.09.18230466992
   PubMed Web of Science ®Google Scholar
• MengJ, LiY, ZhangM, et al. A combination of curcumin, vorinostat and silibinin reverses Abeta-induced nerve cell toxicity via activation of AKT-MDM2-p53 pathway. PeerJ. 2019;7:e6716. doi:10.7717/peerj.671631086728
   PubMed Web of Science ®Google Scholar
• KosasihS, Zhi QinW, Abdul RaniR, et al. Relationship between serum cytokeratin-18, control attenuation parameter, NAFLD fibrosis score, and liver steatosis in nonalcoholic fatty liver disease. Int J Hepatol. 2018;2018:9252536. doi:10.1155/2018/925253630363686
   PubMed Web of Science ®Google Scholar
• ZhangM, PanX, ZouQ, et al. Notch3 ameliorates cardiac fibrosis after myocardial infarction by inhibiting the TGF-beta1/Smad3 pathway. Cardiovasc Toxicol. 2016;16(4):316–324. doi:10.1007/s12012-015-9341-z26487518
   PubMed Web of Science ®Google Scholar
• CaiY, XueY, AnRF. [The expression of EMT associated protein CK-18 and vimentin in gestational trophoblastic disease]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2014;45(6):960–963, 1014.25571724
   PubMedGoogle Scholar
• KongJ, DiC, PiaoJ, et al. Ezrin contributes to cervical cancer progression through induction of epithelial-mesenchymal transition. Oncotarget. 2016;7(15):19631–19642. doi:10.18632/oncotarget.777926933912
   PubMedGoogle Scholar
• ZhuL, FuX, ChenX, HanX, DongP. M2 macrophages induce EMT through the TGF-beta/Smad2 signaling pathway. Cell Biol Int. 2017;41(9):960–968. doi:10.1002/cbin.1078828493530
   PubMed Web of Science ®Google Scholar
• MengXM, Nikolic-PatersonDJ, LanHY. TGF-beta: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–338. doi:10.1038/nrneph.2016.4827108839
   PubMed Web of Science ®Google Scholar
• SistoM, LorussoL, IngravalloG, et al. The TGF-beta1 signaling pathway as an attractive target in the fibrosis pathogenesis of sjogren’s syndrome. Mediators Inflamm. 2018;2018:1965935. doi:10.1155/2018/196593530598637
   PubMed Web of Science ®Google Scholar
• KimJS, HanNK, KimSH, LeeHJ. Silibinin attenuates radiation-induced intestinal fibrosis and reverses epithelial-to-mesenchymal transition. Oncotarget. 2017;8(41):69386–69397. doi:10.18632/oncotarget.2062429050211
   PubMedGoogle Scholar
• FengH, JiaXM, GaoNN, et al. Overexpressed VEPH1 inhibits epithelial-mesenchymal transition, invasion, and migration of human cutaneous melanoma cells through inactivating the TGF-beta signaling pathway. Cell Cycle. 2019;18(21):2860–2875. doi:10.1080/15384101.2019.163819131599708
   PubMed Web of Science ®Google Scholar
• LiangD, ChenH, ZhaoL, et al. Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864(1):133–142. doi:10.1016/j.bbadis.2017.10.01629038049
   PubMed Web of Science ®Google Scholar
• OkazakiH, SatoS, KoyamaK, et al. The novel inhibitor PRI-724 for Wnt/beta-catenin/CBP signaling ameliorates bleomycin-induced pulmonary fibrosis in mice. Exp Lung Res. 2019;45:1–12.31032652
   PubMed Web of Science ®Google Scholar